THERAPY DOSSIER · th-caf1120493ae

Eleutherococcus extract

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Radiation
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 2

1 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT01599169 ↗Injury indicationNAcompleted

Evaluation of the Efficacy and Tolerance of B-Back on the Burnout Syndrome (contains Eleutherococcus senticosus)

Burnout Syndrome

Enrolment: 87 · Results not recorded

NCT03210519 ↗NAcompleted

A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy of Eleutherococcus Senticosus for Anti-inflammation and Improvement of Erythropoietin Hyporesponsiveness in Subjects Under Renal Dialysis

Renal Dialysis

Enrolment: 21 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 6189142 ↗1982Outcome unclear

Peripheral blood changes in Eleutherococcus pretreated mice exposed to acute gamma radiation.

MouseRadiationMalePretreatment before irradiation

Model: Acute gamma irradiation

Extraction: extract · Supplied extraction confidence: 0.25. Machine-extracted fields require source verification.

Loading the evidence…